People on the Move
GenSight Biologics
GenSight Biologics, a company developing gene therapies to improve the vision of people with degenerative retinal and inherited ophthalmologic diseases, has appointed Jean-Philippe Combal as Chief Operating Officer (COO).
Combal will lead operations and develop the company’s products. GenSight’s lead product, GS010, is a gene replacement therapy currently in a Phase I trial for Leber’s hereditary optic neuropathy (LHON), a rare mitochondrial disease that leads to sight loss in teenagers and young adults.
Combal has 23 years’ experience in the pharmaceutical industry, having served as VP of development at Fovea, where he worked on the products that led to the company’s acquisition of Sanofi in 2009.
